原发性胆管细胞癌中Fyn的表达及其与患者预后的关系

Expression of Fyn in Primary Cholangiocarcinoma and Its Relationship with Prognosis of Patients

目的:研究非受体酪氨酸激酶Fyn在原发性胆管细胞癌组织中的表达情况,分析Fyn与临床病理参数之间的关系及其和患者预后的关系。方法:收集113例胆管细胞癌患者的临床资料和病理标本,通过免疫组织化学染色法(免疫组化)检测患者肿瘤组织Fyn中的表达情况,分析患者的临床病理特征,采用卡方检验分析Fyn与临床病理参数之间的关系。Kaplan-Meier法绘制患者生存曲线,Log-rank检验和Cox比例风险模型分析患者预后及影响因素。结果:Fyn的表达水平与肿瘤直径、N分期、组织分化程度有相关性,差异具有统计学意义(P < 0.05)。Fyn高表达患者的总生存期(0S)较Fyn低表达患者短(P < 0.05)。多因素Cox比例风险模型分析显示,高Fyn表达、高龄、组织分化程度低、淋巴结转移皆为影响OS的独立危险因素。结论:癌组织中Fyn的表达会影响胆管癌患者预后,Fyn可能成为胆管癌患者临床诊疗过程中新的观察指标及治疗靶点。

Objective: To study the expression of non-receptor tyrosine kinase Fyn in primary cholangiocarci-noma tissues, and to analyze the relationship between Fyn and clinicopathological parameters and its relationship with patient prognosis. Methods: Clinical data and pathological specimens of 113 patients with cholangiocarcinoma were collected, and the expression of Fyn in tumor tissues of pa-tients was detected by immunohistochemical staining (immunohistochemistry) to analyze the clinicopathological characteristics of patients, and the relationship between Fyn and clinicopatho-logical parameters was analyzed by the chi-square test. The Kaplan-Meier method was used to plot the survival curves of patients, and the Log-rank test and Cox proportional risk model were used to analyze patient prognosis and influencing factors. Results: The expression level of Fyn correlated with tumor diameter, N stage, and tissue differentiation, and the difference was statistically signifi-cant (P < 0.05). The overall survival (0S) of patients with high Fyn expression was shorter than that of patients with low Fyn expression (P < 0.05). Multifactorial Cox proportional risk model analysis showed that high Fyn expression, advanced age, low tissue differentiation, and lymph node metas-tasis were independent risk factors for OS. Conclusion: Fyn expression in cancer tissues affects the prognosis of cholangiocarcinoma patients, and Fyn may become a new observational index and therapeutic target in the clinical treatment of cholangiocarcinoma patients.